Clinical trial · no report yet · Phase 3
NCT03924895
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- NCT03924895 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 352 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 164 | |
| YouTube | 102 | |
| Podcasts | 79 | |
| X videos | 7 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study Evaluating Cystectomy With Perioperative Pembrolizumab and Cystectomy With Perioperative Enfortumab Vedotin and Pembrolizumab Versus Cystectomy Alone in Participants Who Are Cisplatin-Ineligible or Decline Cisplatin With Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Urinary Bladder Cancer, Muscle-invasive
- Interventions
- Pembrolizumab; Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]); Enfortumab Vedotin
- Arms
- Arm A: Pembrolizumab + Surgery · Experimental
- Arm B: Surgery alone · Active comparator
- Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery · Experimental
- Enrollment
- 595
- Primary outcomes
- Event-Free Survival (EFS) Between Arm C: Enfortumab Vedotin + Pembrolizumab + Surgery and Arm B: Surgery Alone
- Sponsor
- Merck Sharp & Dohme LLC with Seagen Inc., Astellas Pharma Global Development, Inc.
- Start
- Jul 24, 2019
- Primary completion
- Jun 6, 2025
- Results posted
- Yes
- Registry record
- NCT03924895 · updated Jun 30, 2026
Publications
linked from the registry- Vulsteke C, Adra N, Danchaivijitr P, Sabadash M, Rodriguez-Vida A, Zhang Z, Atduev V, Goger YE, Rausch S, Kang SH, Loriot Y, Bedke J, Galsky MD, O'Donnell PH, von Amsberg G, Alimohamed N, Sulimka G, Gupta S, Paramonov V, Nakane K, Mihm M, Meng C, Huang CD, Ramamurthy C, Homet Moreno B, Ullen A; KEYNOTE-905/EV-303 Investigators. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 2;394(13):1257-1269. doi: 10.1056/NEJMoa2511674. Epub 2026 Feb 18. PubMed 41707170
- Galsky MD, Hoimes CJ, Necchi A, Shore N, Witjes JA, Steinberg G, Bedke J, Nishiyama H, Fang X, Kataria R, Sbar E, Jia X, Siefker-Radtke A. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. Future Oncol. 2021 Aug;17(24):3137-3150. doi: 10.2217/fon-2021-0273. Epub 2021 May 19. PubMed 34008425